1964
Construction plans
“Highly specific verapamil/nifedipine/diltiazem-type calcium channel blockers have opened up completely new perspectives in therapy and research.”
“Their great therapeutic potential is ultimately based on the same fundamental mechanisms of action.”
“Dihydropyridine calcium channel blockers have the strongest vasodilatory effects; for example, in the treatment of arterial hypertension.”
A. Fleckenstein
Professor of Physiology
Discoverer of calcium channel blockers
1966
Port of registration
Following research by Dr Bossert and Dr Vater, nifedipine enters Bayer as ‘BAYa 1040’.
Dr F. Bossert
Bayer chemist
Dr W. Vater
Bayer pharmacologist
1975
Naming of the ship
Launch of Adalat® in Germany as a cardioprotective coronary therapeutic agent for the management of angina
Setting sail
The launch of Adalat® was driven by a strong communications programme.
Slogans: “There is only one Adalat®” and “The challenge to your coronary therapy”
1979
Jollyboat
Adalat® 5mg – the brand expands
1980
New Worlds
Adalat® was introduced in the USA.
1981
New Target
A longer-acting formulation is developed as Adalat® Retard and is indicated for the management of essential hypertension and angina.
1984
Extension of the fleet
Additions to the clinical range with Sali Adalat®, Adalat® intra-coronary, Adalat® i.v. and Adalat® 20.
1985
New loadings
Maturity date of patent. Bayer responded by developing Tredalat®, Adalat® SL and Adalat® T10.
1990
Anchor in the storm
INTACT: INTACT results, published in The Lancet, showed that, in patients with mild CAD, Adalat® slows cardiovascular disease progression – evaluated by the detection of new atherosclerotic lesions.
Lichtlen PR, et al. Lancet 1990;335:1109–13.
1991
Stay on target for 24 hours
Adalat® OROS/GITS once-daily is developed. The unique galenic formulation of Adalat® OROS/GITS remains unsurpassed. From both convenience and safety profile perspectives, the new Adalat® OROS/GITS formulation improves the effectiveness of Adalat®. Take a short look at how Adalat® OROS/GITS passes through the digestive tract and ensures constant plasma nifedipine levels over 24 hours.
2000
Land IN SIGHT
Advanced protection from cardiovascular (CV) events – Adalat® GITS saves lives. With a CV risk reduction of 50%, INSIGHT showed that Adalat® GITS is as effective as a diuretic combination in reducing blood pressure and CV risk. The study demonstrated that Adalat® GITS preserves renal function and prevents the development of diabetes and atherosclerotic vessel damage. Further results of INSIGHT suggest that Adalat® GITS slows the progression of atherosclerosis by reducing coronary calcification and intima-media thickening.
Brown MJ, et al. Lancet 2000;356:366–72.
2001
A fresh breeze of success
ENCORE demonstrated that Adalat® GITS treatment significantly improved endothelial function, even in the most constricting coronary artery segment. This supports the hypothesis that Adalat® GITS treatment benefits the vascular system, as indicated by the INSIGHT side-arm study results.
ENCORE Investigators. Circulation 2003;107:422–8.
2004
Full speed ahead
ACTION
Adalat® GITS administered in addition to best-practice therapy for coronary artery disease
The ACTION primary analysis revealed an impressive 11% overall risk reduction in cardiovascular events and procedures.1
The Hypertension subgroup analysis showed that Adalat® GITS has even greater benefits in patients with hypertension at baseline:2
· 13% risk reduction in cardiovascular mortality and events
· 38% reduction in the incidence of new overt heart failure
· 33% reduction in the incidence of debilitating stroke i
1. Poole-Wilson P, et al. Lancet 2004;364:849–57.
2. Lubsen J, et al. J Hypertension 2005; 23:641–8.
Future
Future ahoy
30 years of Adalat® – 30 years of experience, effectiveness and safety. The course was never easy, but quality of research allowed new territories to be conquered. Today, Adalat® has a strong position and is relied on by millions of doctors and patients. To maintain this position, we continue our research and investment, so you can remain on track to the future.
Further ACTION study subanalyses investigating risk management,1 safety,2 atrial fibrillation,3 coronary calcification,4 heart failure,5 systolic blood pressure6 and healthcare utlisation7 emphasise the benefits of Adalat® for patients with coronary heart disease, angina pectoris and hypertension.
The journey continues…
1. Clayton T, et al. BMJ 2005;331:869–73.
2. Poole-Wilson P, et al. Cardiovasc Drugs Ther 2006;20:45–54.
3. Otterstad JE, et al. Scan Cardiovasc J 2006;40:152–9.
4. Motro M, et al. Cardiology 2007;107:165–171.
5. Sutton GC, et al. Eur J Heart Failure 2006. doi:10.1016/j.ejheart.2006.09.002.
6. Lubsen J, et al. J Clin Epidemiol 2006. doi:10.1016/j.jclinepi.2006.10.015.
7. Poole-Wilson PA, et al. J Clin Epidemiol 2006. doi:10.1016/j.jclinepi.2006.10.016.
